Anesthesia | Eklavya Medical

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 251 person Asked by .

bookmark_add

Define FRC and discuss its physiological significance during general anaesthesia. Enumerate the factors that decrease FRC perioperatively. Explain the mechanism and clinical utility of PEEP in restoring FRC.

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Long Answer

Functional Residual Capacity — Definition, Perioperative Significance, PEEP Restoration

Define FRC and discuss its physiological significance during general anaesthesia. Enumerate the factors that decrease FRC perioperatively. Explain the mechanism and clinical utility of PEEP in restoring FRC. [3+3+4]

⚙ Core Concept

Functional Residual Capacity (FRC) is the lung volume at end of a passive expiration — the equilibrium between the outward recoil of the chest wall and the inward elastic recoil of the lungs. It is the most anaesthesia-relevant lung volume because it determines the O₂ reserve during apnoea, governs small airway patency, and sets the position of the lung on its compliance curve. General anaesthesia consistently and predictably reduces FRC by 15–20% — the single most important perioperative respiratory change. (Nunn's Applied Respiratory Physiology 8th Ed; Hedenstierna G — BJA 2003; Miller's Anaesthesia 9th Ed)

A. Definition and Composition of FRC 1 mark

Definition: FRC is the volume of gas remaining in the lungs at the end of a quiet, passive expiration — when the respiratory muscles are at rest and no active inspiratory or expiratory effort is occurring; it is the resting equilibrium volume of the respiratory system
Composition: FRC = Expiratory Reserve Volume (ERV) + Residual Volume (RV); normal adult FRC ≈ 2.5–3.0 L (supine); ≈ 3.0–3.5 L (upright)
Determinants: FRC is set by the balance between: outward recoil of the chest wall (which tends to spring outward) and inward elastic recoil of the lungs (which tends to collapse); when these two forces balance → FRC is established; any factor that reduces chest wall outward recoil or increases inward lung recoil → ↓ FRC

B. Physiological Significance of FRC During General Anaesthesia 2 marks

Role of FRC	Clinical Significance
O₂ reservoir during apnoea	FRC provides the alveolar O₂ store that maintains PaO₂ during periods of apnoea (e.g., laryngoscopy, intubation); normal FRC (2.5 L at FiO₂ 1.0 after pre-oxygenation) allows safe apnoea for 5–8 minutes; reduced FRC (obese, pregnant) → rapid desaturation within 1–2 min; this is why pre-oxygenation and HFNO matter
Prevents small airway closure	At FRC, the lung volume is above closing capacity (CC) in normal adults — small airways remain open throughout tidal breathing; if FRC falls below CC → small airways close during normal tidal expiration → atelectasis → V/Q mismatch → hypoxaemia; this is the mechanism of GA-induced hypoxaemia
Positions lung on optimal compliance curve	At FRC, the lung is on the steep, linear part of the pressure-volume curve — small pressure changes produce large volume changes (high compliance); at very low or high volumes, compliance is reduced; loss of FRC → reduced lung compliance → ↑ work of breathing
Buffers alveolar gas tensions	The large FRC volume buffers moment-to-moment changes in alveolar PO₂ and PCO₂ between breaths; a reduced FRC means smaller buffer → more oscillation in alveolar gas tensions between breaths

C. Factors Decreasing FRC Perioperatively 3 marks

General anaesthesia itself (most important): GA reduces FRC by 15–20% (400–500 mL) within minutes of induction regardless of the agent used; mechanism: loss of tonic inspiratory muscle activity (diaphragm and intercostals relax under GA) → chest wall loses its outward elastic recoil contribution → equilibrium shifts inward → FRC falls; most of this reduction is due to cephalad diaphragm displacement
Supine position: gravity causes the abdominal viscera to push the diaphragm cephalad → ↓ FRC by ~500 mL from upright to supine in the awake patient; this positional reduction is ADDITIVE to the GA-induced reduction
Muscle paralysis: NMBs eliminate residual tonic diaphragm activity → further cephalad diaphragm shift → additional FRC reduction beyond GA alone
Obesity: excess abdominal fat → ↑ intra-abdominal pressure → further diaphragm elevation → FRC may be critically reduced; morbidly obese patients (BMI >40) may have FRC approaching or below CC even when awake and sitting → closing capacity may exceed FRC → airway closure during normal breathing
Pregnancy: gravid uterus elevates the diaphragm → FRC reduced by 20–25% at term; combined with increased O₂ consumption (20–30% above normal) → extremely rapid desaturation during apnoea
Pulmonary oedema, pleural effusion: fluid within or around the lungs → compression of alveoli → ↓ FRC
ARDS/diffuse lung disease: extensive alveolar collapse and consolidation → markedly reduced FRC (the “baby lung” concept)

D. Mechanism and Clinical Utility of PEEP in Restoring FRC 4 marks

Mechanism — how PEEP restores FRC: PEEP (Positive End-Expiratory Pressure) maintains airway pressure above atmospheric at end-expiration; this prevents the complete deflation of alveoli that would otherwise occur in anaesthetised, supine, relaxed patients; the maintained positive pressure at end-expiration: (1) props open alveoli that would have collapsed (recruits atelectatic units); (2) stabilises already-open alveoli (prevents end-expiratory derecruitment); (3) shifts the end-expiratory lung volume back toward the pre-GA FRC or above it → the effective FRC is increased by approximately the amount of volume recruited at each PEEP level
PEEP and closing capacity: by raising the end-expiratory lung volume above closing capacity, PEEP prevents small airway closure during tidal breathing → ↓ V/Q mismatch → ↑ PaO₂; the goal is to select a PEEP level that keeps the lung above CC throughout the tidal cycle
Clinical utility: Routine intraoperative PEEP 5–8 cmH₂O (the “lung-protective ventilation” standard for general anaesthesia): prevents atelectasis, maintains oxygenation, reduces post-operative pulmonary complications; LAS3 trial and PROVE Network support PEEP 6–8 cmH₂O for routine use; PEEP in ARDS: higher PEEP (10–18 cmH₂O) with 6 mL/kg IBW tidal volumes (ARDSNet protocol) → reduces mortality; PEEP in obese patients requires higher PEEP (10–12 cmH₂O)
Adverse effects of PEEP: ↑ intrathoracic pressure → ↓ venous return → ↓ CO (particularly at PEEP >10–12 cmH₂O or in hypovolaemic patients); ↑ dead space (overdistension of already-open alveoli → wasted ventilation); ↑ risk of barotrauma at very high levels; risk of worsening V/Q in non-recruitable regions (increases West Zone 1 in non-dependent zones)

💬 Viva Corner

Q. How does closing capacity relate to FRC and what happens when CC exceeds FRC?

Closing capacity (CC) is the lung volume at which small airways in the dependent lung zones begin to close during expiration. In young healthy adults, CC is well below FRC (approximately equal to Residual Volume) — airways remain open throughout the entire tidal breathing range, and V/Q matching is excellent. As age increases, CC rises and FRC falls → in adults over 65 years upright, and over 44 years supine, CC begins to approach or exceed FRC. When CC exceeds FRC: small airways close during tidal expiration → trapped gas behind closed airways → ventilation ceases to dependent alveoli while perfusion continues → true intrapulmonary shunt → hypoxaemia. Under GA, FRC falls by 400–500 mL while CC is relatively unchanged → this dramatically worsens the CC-FRC relationship → even patients who had CC below FRC when awake may develop CC above FRC under GA — this is the mechanism of GA-induced atelectasis. PEEP raises the end-expiratory lung volume above CC → reopens the small airways → restores V/Q matching → improves oxygenation.

★ Examiner's Pearl

The three-part answer must address: definition (equilibrium volume — balance of chest wall outward recoil vs lung elastic recoil); factors reducing FRC (GA = 400 mL, supine = 500 mL, obesity, pregnancy, paralysis — all additive); and PEEP mechanism (maintains end-expiratory pressure above CC → recruits alveoli → prevents airway closure). The FRC = ERV + RV decomposition and the normal values (2.5–3.0 L supine; ≈3.5 L upright) are specific numbers frequently asked.

References: Nunn's Applied Respiratory Physiology, 8th Ed. Hedenstierna G, Edmark L. The effects of anesthesia and muscle paralysis on the respiratory system (Intensive Care Med 2005;31:1327-1335). PROVE Network — Intraoperative Protective Ventilation (NEJM 2014;370:1987-1997). Miller RD et al. Miller's Anaesthesia, 9th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 252 person Asked by .

bookmark_add

Write short notes on: (a) Zones of West in the lung and their significance under mechanical ventilation [5] (b) Hypoxic Pulmonary Vasoconstriction (HPV) and factors blunting it [5]

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Short Notes

West Zones of the Lung & Hypoxic Pulmonary Vasoconstriction — Mechanical Ventilation Effects

Write short notes on: (a) Zones of West in the lung and their significance under mechanical ventilation [5] (b) Hypoxic Pulmonary Vasoconstriction (HPV) and factors blunting it [5]

A. Zones of West 5 marks

⚙ Core Concept

West's three-zone model (published 1964) describes the gravitational distribution of pulmonary blood flow relative to alveolar pressure — explaining why the lung is not uniformly perfused and why V/Q ratios vary from apex to base. Under mechanical ventilation, positive pressure changes the zone distribution significantly, with important clinical consequences for oxygenation and haemodynamics.

Zone 1 (apex): Palv > Part > Pven; alveolar pressure exceeds arterial pressure → alveoli collapse the capillaries → no blood flow → pure dead space; minimal in normal spontaneous breathing; Zone 1 EXPANDS under IPPV + PEEP (raises alveolar pressure above pulmonary arterial pressure) → ↑ dead space → ↑ minute ventilation required to maintain normocapnia
Zone 2 (middle): Part > Palv > Pven; blood flow determined by the arterial-alveolar pressure difference — the “waterfall” or “Starling resistor” effect; blood flow is intermittent; largest zone in the upright lung during normal breathing
Zone 3 (base): Part > Pven > Palv; both arterial and venous pressures exceed alveolar pressure → continuous blood flow determined by the normal arterio-venous pressure gradient; dependent lung base receives the greatest blood flow; most physiological gas exchange occurs here
Zone 4 (very base — extra-alveolar vessels): at very low lung volumes (below FRC), extra-alveolar vessels are compressed by the lung parenchyma → paradoxically reduced blood flow despite high hydrostatic pressure; occurs when FRC is critically low (ARDS, obesity under GA)

Zone	Pressure Relationship	Blood Flow	V/Q Ratio
Zone 1 (apex)	Palv > Part > Pven	Zero (dead space)	Infinity (wasted ventilation)
Zone 2 (middle)	Part > Palv > Pven	Intermittent (waterfall)	High (>1) — V relative excess
Zone 3 (base)	Part > Pven > Palv	Continuous maximum	Low (<1) — Q relative excess
Zone 4 (extreme base)	Part > Pven > Palv but extra-alveolar compression	Reduced	Variable ↑ (low flow)

Significance during mechanical ventilation: IPPV raises mean intrathoracic pressure → Zone 1 expands (apex becomes dead space) → physiological dead space increases; clinically: ETCO₂ underestimates PaCO₂ (the PaCO₂-ETCO₂ gradient widens from normal 2–5 mmHg to >10 mmHg in patients with large Zone 1); during OLV (one-lung ventilation), the non-dependent lung is collapsed → Zone 3 predominates in the collapsed lung → V/Q = 0 (shunt); total shunt fraction from the non-ventilated lung determines the degree of hypoxaemia during OLV

B. Hypoxic Pulmonary Vasoconstriction 5 marks

⚙ Core Concept

HPV is the PROTECTIVE, auto-regulatory mechanism by which the pulmonary vasculature constricts in response to alveolar hypoxia — diverting blood away from poorly ventilated (hypoxic) alveoli to better-ventilated ones, thereby maintaining V/Q matching. It is the OPPOSITE of the systemic circulation's response to hypoxia. HPV is the primary mechanism limiting the V/Q mismatch from atelectasis and one-lung ventilation.

Stimulus: primarily ALVEOLAR O₂ tension (PAO₂) — not arterial PaO₂; PAO₂ threshold for HPV ≈ 60–70 mmHg; response is biphasic: initial fast phase (minutes) followed by sustained late phase (hours); mixed venous PO₂ also contributes
Mechanism: hypoxia → O₂-sensitive K⁺ channels in pulmonary artery smooth muscle cells inhibited → membrane depolarisation → voltage-gated Ca²⁺ channels open → Ca²⁺ influx → smooth muscle contraction → ↑ pulmonary vascular resistance in the hypoxic region → ↓ blood flow to that region; endothelin-1 amplifies HPV; NO production simultaneously reduced
Clinical importance: HPV limits shunt during OLV and atelectasis; the non-dependent (operated, collapsed) lung during OLV undergoes HPV → blood is diverted to the ventilated lung → limits hypoxaemia; HPV can reduce the shunt fraction in the collapsed lung from 100% (no HPV) to ~50% of the collapsed lung's blood flow

Category	Factor	Mechanism
Anaesthetic agents	Volatile agents (dose-dependent) — halothane > isoflurane > sevoflurane > desflurane; all blunt HPV; IV propofol does NOT blunt HPV	Volatile agents relax pulmonary vascular smooth muscle → blunt HPV-mediated vasoconstriction → ↑ shunt during OLV; propofol has no effect on HPV at clinical concentrations
Vasodilators	Sodium nitroprusside, nitroglycerin, calcium channel blockers, sildenafil, inhaled NO	Direct pulmonary vasodilation → vasodilate hypoxic AND normoxic regions → abolish the selective regional vasoconstriction of HPV
High or low FiO₂	Very high FiO₂ (1.0) in the ventilated lung may blunt HPV in the non-ventilated lung	High PvO₂ reaching the non-ventilated lung may blunt HPV; some use FiO₂ 0.7–0.8 to maintain HPV stimulus while preventing hypoxaemia
Alkalosis	Respiratory or metabolic alkalosis (hypocapnia)	Alkalosis directly relaxes pulmonary vascular smooth muscle → blunts HPV; permissive hypercapnia may enhance HPV
Increased pulmonary vascular pressure	Hyperdynamic states (fever, sepsis), volume overload	High perfusion pressure through the hypoxic region overcomes HPV-mediated resistance

💬 Viva Corner

Q. Why is TIVA preferred over volatile anaesthesia during one-lung ventilation?

During OLV, the non-ventilated lung represents a complete shunt. HPV is the only physiological mechanism limiting this shunt, diverting up to 50% of that lung's blood flow to the ventilated lung. Volatile agents dose-dependently blunt HPV by relaxing pulmonary artery smooth muscle → greater shunt → worse hypoxaemia. Studies confirm PaO₂ during OLV is consistently 15–25 mmHg higher with propofol TIVA than with equi-MAC volatile anaesthesia. TIVA also reduces PONV and has lower environmental impact, making propofol-remifentanil the preferred technique for OLV in thoracic surgery.

★ Examiner's Pearl

Zone pressure relationships must be reproduced exactly in order (Zone 1: Palv > Part; Zone 2: Part > Palv > Pven; Zone 3: Part > Pven > Palv). HPV blunting by volatile agents (dose-dependent; propofol does NOT blunt HPV) is the highest-yield clinical application. Zone 1 expansion by IPPV (↑ dead space → ↑ PaCO₂-ETCO₂ gradient) is the most tested clinical consequence.

References: West JB et al. Distribution of blood flow in isolated lung (J Appl Physiol 1964;19:713-724). Marshall BE, Wyche MQ. Hypoxic pulmonary vasoconstriction (Anesthesiology 1972;37:588-609). Benumof JL. Anesthesia for Thoracic Surgery, 2nd Ed. Nunn's Applied Respiratory Physiology, 8th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 253 person Asked by .

bookmark_add

Detail the boundaries, contents, and ligaments traversed during epidural puncture [5]. Explain the physiological factors governing the spread of local anaesthetics within the epidural space [5].

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Long Answer

Epidural Space Anatomy — Boundaries, Contents, Ligaments & LA Spread Factors

Detail the boundaries, contents, and ligaments traversed during epidural puncture [5]. Explain the physiological factors governing the spread of local anaesthetics within the epidural space [5].

⚙ Core Concept

The epidural space is the potential space surrounding the dural sac within the vertebral canal — understanding its three-dimensional anatomy is the foundation of safe and effective epidural anaesthesia. The spread of local anaesthetic within this space is determined by multiple interacting factors, explaining why two patients given identical doses may achieve dramatically different block heights. (Hadzic A — Textbook of Regional Anesthesia; Macintosh RR; Miller's Anaesthesia 9th Ed)

A. Anatomy of the Epidural Space 5 marks

Boundaries

Superior: foramen magnum (dura fuses with skull periosteum → closed space superiorly)
Inferior: sacrococcygeal membrane (sacral hiatus — entry point for caudal epidural anaesthesia)
Anterior: posterior longitudinal ligament (PLL) covering the vertebral bodies and discs
Posterior: ligamentum flavum (LF) and anterior surface of the laminae (the firm resistance felt during loss-of-resistance technique)
Lateral: pedicles and intervertebral foramina (route by which epidurally-injected LA reaches nerve roots)

Contents of the Epidural Space

Structure	Significance
Epidural fat (adipose tissue)	Fills the posterior epidural space; acts as a depot for lipid-soluble LAs; reduced in the elderly (spreads further → higher block for same dose); more fat in obese patients
Epidural venous plexus (Batson's plexus)	Valveless network communicating with abdominal/pelvic veins; engorged in pregnancy (IVC compression → ↑ venous pressure → reduced space volume → higher block); inadvertent intravascular injection → LAST
Spinal nerve roots (dural sleeves)	Primary target for epidural anaesthesia; LA must penetrate the dural sleeve to block the nerve roots
Lymphatics	Minor role in clearance of epidural drugs
Spinal (radicular) arteries	Supply the spinal cord; accidental injection → spinal cord infarction; rare but catastrophic

Ligaments Traversed (Posterior Approach — Midline)

Skin and subcutaneous tissue
Supraspinous ligament: connects tips of spinous processes; dense fibrous cord; tougher in elderly and lumbar region
Interspinous ligament: connects adjacent spinous processes; less dense; “softer” feel
Ligamentum flavum (LF): the KEY ligament — 70–80% yellow elastin fibres; produces the characteristic “loss of resistance”; thickest in lumbar region (3–5 mm); thinnest thoracic (2–3 mm); may be discontinuous midline → false loss of resistance
Epidural space (destination — negative pressure encountered on entry)

⇗ Depth from Skin to Epidural Space

Average 4–6 cm in adults; range 3–8 cm depending on BMI, level of puncture, patient habitus. Greater at thoracic levels, in obese patients, and in lateral decubitus.

B. Factors Governing LA Spread in the Epidural Space 5 marks

Factor	Effect on Spread	Mechanism
Volume of LA injected (most important)	↑ Volume → ↑ spread; 1–2 dermatomes per mL	Higher volume increases longitudinal spread; volume is the PRIMARY determinant for epidural (unlike spinal where baricity/position dominate)
Age	Elderly → higher block for same dose	Reduced epidural fat and smaller foramina → less LA escapes paravertebrally → more spreads longitudinally; older nerve fibres more susceptible
Pregnancy	Higher block for same volume	Engorged Batson's plexus → ↓ effective epidural space volume → same volume spreads further; ↑ nerve sensitivity (progesterone effect)
Speed of injection	Faster → unpredictably wider spread	Rapid injection creates turbulence/pressure wave driving LA cephalad; slow injection = controlled spread
Posture/positioning	Head-up → caudal spread; Trendelenburg → cephalad spread	Gravity influences initial distribution; effect diminishes as LA spreads through fat
Level of injection	Thoracic insertion → smaller volume needed	Thoracic epidural space is narrower, less fat → same volume gives greater spread
Concentration/pH/pKa	Alkalinisation (NaHCO₃ 8.4% 0.1 mEq/mL) speeds onset	Non-ionised base form penetrates nerve membranes; alkalinisation shifts more drug to non-ionised form
Vasoconstrictors (adrenaline)	1:200,000 prolongs duration by 30–50%	Vasoconstriction slows systemic absorption → more LA remains at site of action → also ↓ LAST risk

💬 Viva Corner

Q. A 70-year-old woman receives an epidural top-up of 15 mL bupivacaine 0.5% and develops a block to T2 — far higher than expected. What factors contributed?

Multiple age-related factors converge: reduced epidural fat (spreads further), sclerosis/calcification of intervertebral foramina (less lateral escape, forces more cephalad spread), reduced neuronal sensitivity threshold (lower concentrations achieve equivalent block), and reduced total epidural space volume from osteoarthritic changes. The combination means 15 mL in a 70-year-old may achieve the spread that 20–22 mL would in a 30-year-old. Management: reduce epidural dose by 20–30% in the elderly; inject incrementally with neurological assessment; have vasopressors, atropine, and airway equipment available; never inject full intended doses rapidly in elderly patients.

★ Examiner's Pearl

Ligaments traversed in order (supraspinous → interspinous → ligamentum flavum → epidural space) must be reproduced with characteristics of each. Ligamentum flavum: 70–80% elastin, produces “loss-of-resistance”, thickest lumbar (3–5 mm). Volume is the PRIMARY determinant of spread in epidural (unlike spinal where baricity + position dominate). Pregnancy → ↑ block height from engorged Batson's plexus is the highest-yield pregnancy-specific fact.

References: Hadzic A. Textbook of Regional Anaesthesia and Acute Pain Management, 2nd Ed. Netter FH. Atlas of Human Anatomy. Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapters 49 and 56.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 254 person Asked by .

bookmark_add

Describe the principles of Train-of-Four (TOF) and Double Burst Stimulation (DBS) [4]. Explain the phenomenon of 'fade' and 'post-tetanic facilitation' in depolarising vs. non-depolarising blocks [6].

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Long Answer

Neuromuscular Blockade Monitoring — TOF, DBS, Fade & Post-Tetanic Facilitation

Describe the principles of Train-of-Four (TOF) and Double Burst Stimulation (DBS) [4]. Explain the phenomenon of 'fade' and 'post-tetanic facilitation' in depolarising vs. non-depolarising blocks [6].

⚙ Core Concept

Neuromuscular monitoring is the gold-standard tool for guiding NMB dosing, timing reversal, and confirming adequate recovery before extubation. The specific patterns of fade and post-tetanic facilitation distinguish depolarising from non-depolarising block at a fundamental mechanistic level. (Murphy GS; Naguib M — Anesthesiology; Miller's Anaesthesia 9th Ed)

A. Train-of-Four (TOF) Monitoring 2 marks

Principle: four supramaximal electrical stimuli (0.2 ms pulse width) at 2 Hz to the ulnar nerve at the wrist; four twitches (T1–T4) measured by acceleromyography
TOF Count: number of detectable twitches (0–4); T1 returns first → count 1/4; T4 returns last → count 4/4
TOF Ratio (TOFR): T4/T1 amplitude ratio; TOFR ≥0.9 = adequate recovery (safe extubation); 0.7–0.9 = pharyngeal dysfunction/aspiration risk; <0.4 = obvious weakness
Monitoring sites: adductor pollicis (ulnar — standard); corrugator supercilii (facial — surrogate for laryngeal muscles); orbicularis oculi

B. Double Burst Stimulation (DBS) 2 marks

Principle: two short bursts of 50 Hz tetanic stimulation (each = 3 × 0.2 ms pulses), separated by 750 ms; most common variant DBS₃,₃
Clinical advantage: fade between the two DBS responses is more detectable by tactile/visual assessment than TOF fade; the human finger CANNOT reliably detect TOF fade between 0.4–0.7 TOFR but can detect fade in DBS
Limitation: DBS does NOT eliminate the need for quantitative accelerometry — cannot reliably detect TOFR >0.7 by tactile assessment

C. Fade and Its Mechanism 3 marks

Definition: progressive decrease in twitch amplitude during repetitive stimulation — T4 smaller than T1 in non-depolarising block; TOFR = T4/T1 < 1.0
Mechanism: presynaptic nicotinic receptors normally facilitate ACh mobilisation during repetitive firing; non-depolarising NMBs block BOTH postsynaptic AND presynaptic nicotinic receptors → impaired ACh mobilisation → progressively less ACh available → successive end-plate potentials decrease → fade
Non-depolarising block: FADE IS PRESENT during TOF and tetanic stimulation — the hallmark diagnostic feature

D. Post-Tetanic Facilitation (PTF) 3 marks

Phenomenon: after brief tetanic stimulation (50 Hz for 5 seconds), subsequent single-twitch/TOF responses are temporarily ENHANCED beyond pre-tetanic level
Mechanism: tetanic stimulation → massive presynaptic Ca²⁺ influx → very large ACh release overwhelms postsynaptic competitive block; terminal Ca²⁺ load also temporarily increases ACh mobilisation for 1–3 minutes
Post-Tetanic Count (PTC): twitches detectable in 5 seconds following tetanic stimulus; used during PROFOUND non-depolarising block (TOF count = 0); PTC 1–5 = very deep block; PTC >10 = recovery approaching

E. Comparison: Depolarising vs Non-Depolarising Block Patterns

Feature	Depolarising Block (Succinylcholine)	Non-Depolarising Block (Rocuronium, Vecuronium)
TOF fade	NO FADE — all four twitches decrease equally	FADE PRESENT — T4 < T1 (presynaptic ACh mobilisation impaired)
Post-tetanic facilitation	NOT PRESENT	PRESENT — post-tetanic twitches enhanced
Sustained tetanus	Yes — sustained contraction	Fade during tetanus — cannot sustain tetanic contraction
Reversal possible	No reversal agents; spontaneous recovery (plasma cholinesterase)	Neostigmine or sugammadex (for steroidal NMBs)

💬 Viva Corner

Q. Why does fade occur with non-depolarising NMBs but not with succinylcholine?

Non-depolarising NMBs block BOTH postsynaptic and presynaptic nicotinic receptors. The presynaptic auto-receptor normally acts as positive feedback signalling “release more ACh” during rapid firing; blocking it impairs replenishment of the readily-releasable ACh pool → each successive end-plate potential is smaller → T4 < T1 = FADE. Succinylcholine causes depolarisation as a postsynaptic agonist without significantly impairing presynaptic ACh mobilisation → the feedback loop remains intact → all four twitches decrease equally → NO FADE. Similarly, tetanic stimulation enhances ACh release with succinylcholine present, but the postsynaptic receptor is already depolarised-and-blocked, so the extra ACh cannot overcome the block → no post-tetanic facilitation.

★ Examiner's Pearl

The four-part comparison must be reproduced: Depolarising: no fade + no PTF + sustained tetanus. Non-depolarising: FADE present + PTF present + unsustained tetanus. The mechanism of fade (presynaptic nicotinic receptor blockade impairs ACh mobilisation) is the most tested mechanistic explanation. TOFR ≥0.9 for safe extubation (not head-lift ≥5 seconds which only requires TOFR ≥0.6) must be cited.

References: Murphy GS et al. Residual neuromuscular blockade (Anesth Analg 2008;107:130-137). Naguib M et al. Advances in neurobiology of the NMJ (Anesthesiology 2002;96:202-231). Miller RD et al. Miller's Anaesthesia, 9th Ed, Chapter 34.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 255 person Asked by .

bookmark_add

Describe the pharmacology of dexmedetomidine: (a) Mechanism of action and receptor selectivity profile [3] (b) Clinical applications in modern anaesthesia and ICU [4] (c) Adverse effects and contraindications [3].

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Long Answer

Dexmedetomidine — Mechanism, Receptor Selectivity, Clinical Applications & Adverse Effects

Describe the pharmacology of dexmedetomidine: (a) Mechanism of action and receptor selectivity profile [3] (b) Clinical applications in modern anaesthesia and ICU [4] (c) Adverse effects and contraindications [3].

⚙ Core Concept

Dexmedetomidine (Precedex) is a highly selective α₂-adrenoceptor agonist with a selectivity ratio of 1600:1 (α₂:α₁) — 8-fold more selective than clonidine (200:1). Its unique property of producing sedation through the locus coeruleus (mimicking natural sleep) without respiratory depression makes it the only sedative suitable for awake procedures requiring patient cooperation and for ICU sedation where respiratory drive must be preserved. (Kamibayashi T, Mazez M — Anesthesiology 2000; SEDCOM trial JAMA 2009; MENDS trial JAMA 2007; Miller's Anaesthesia 9th Ed)

A. Mechanism of Action & Receptor Profile 3 marks

Receptor: α₂-adrenoceptor agonist; subtypes α₂A (predominant — CNS sedation, analgesia, sympatholysis), α₂B (peripheral vasoconstriction, anti-shivering), α₂C (CNS modulation, adrenal medulla)
Selectivity: α₂:α₁ ratio = 1600:1 (vs clonidine 200:1)
Central mechanism — sedation/analgesia: α₂A activation in the locus coeruleus → hyperpolarisation via Gᵢ protein → ↓ noradrenaline release → ↓ arousal → sedation; EEG resembles natural NREM sleep, unlike GABA-mediated agents which suppress both sleep and arousal pathways — producing unique “rousable cooperative sedation”
Analgesia mechanism: α₂ receptors in the dorsal horn → presynaptic inhibition of substance P release; modest as sole analgesic — primarily an adjuvant
Sympatholysis: α₂ agonism → ↓ noradrenaline release → ↓ sympathetic tone → ↓ HR, ↓ BP

B. Clinical Applications 4 marks

Application	Dose/Protocol	Rationale
ICU sedation (primary indication)	0.2–1.4 mcg/kg/hr IV; loading 1 mcg/kg over 10 min in stable patients; target RASS 0 to −2	SEDCOM trial: vs midazolam — less delirium, fewer ventilator days; MENDS trial: vs lorazepam — more delirium-free days; PADIS 2018 recommends over benzodiazepines
Awake fiberoptic intubation (AFOI)	Loading 1 mcg/kg over 10 min; maintenance 0.4–0.7 mcg/kg/hr	Rousable cooperative sedation without respiratory depression; anxiolytic; blunts haemodynamic response to instrumentation
Awake craniotomy	Titrated to conscious sedation; stopped during mapping	Maintains cooperation for neurological testing without respiratory compromise
Procedural sedation (MRI, bronchoscopy)	0.5–1 mcg/kg loading then 0.2–0.7 mcg/kg/hr	Avoids respiratory depression where airway support is limited; preserves airway reflexes
Paediatric premedication	Intranasal 1–2 mcg/kg (off-label); oral 1–2 mcg/kg	Non-IV route; calm cooperative sedation; avoids paradoxical agitation seen with midazolam
Adjunct for regional anaesthesia	Perineural 50–100 mcg; intrathecal 3–5 mcg	α₂ receptors on peripheral nerve/spinal cord prolong analgesia; motor-sparing
Blunting haemodynamic response	IV bolus 0.5–1 mcg/kg before laryngoscopy	Attenuates sympathetic surge; useful in hypertensive patients, IHD, phaeochromocytoma

C. Adverse Effects and Contraindications 3 marks

Bradycardia: most common significant adverse effect; from central sympatholysis + possible direct SA node effect; treatment: atropine 0.5 mg IV, glycopyrrolate 0.2 mg IV, dose reduction, avoid rapid boluses
Biphasic blood pressure response: initial transient hypertension (peripheral α₂B vasoconstriction with rapid bolus) followed by sustained hypotension (central sympatholysis); give loading dose slowly over 10 minutes
Respiratory effects: minimal at clinical doses — does NOT cause clinically significant respiratory depression (key safety advantage over opioids/benzodiazepines)
Paradoxical agitation: rarely seen in paediatric patients
Contraindications: advanced heart block without pacemaker; severe hepatic failure (exclusive hepatic metabolism); sick sinus syndrome without pacemaker; caution in acute cerebrovascular events

💬 Viva Corner

Q. Why is dexmedetomidine preferred over midazolam for ICU sedation according to current guidelines?

PADIS 2018 recommends dexmedetomidine over benzodiazepines for non-deeply sedated ventilated ICU patients, based on SEDCOM (fewer delirium days, ~1.9 days shorter time to extubation) and MENDS (more delirium-free/coma-free days) trials. Mechanistically, dexmedetomidine sedates via the locus coeruleus, producing a physiological NREM sleep-like EEG that preserves sleep architecture, whereas benzodiazepines suppress the cortex via GABA-A and disrupt normal sleep, contributing to delirium via circadian disruption and inflammatory amplification. Dexmedetomidine also lacks respiratory depression and accumulates less than long-acting benzodiazepines in organ failure.

★ Examiner's Pearl

α₂:α₁ selectivity = 1600:1 (dexmedetomidine) vs 200:1 (clonidine). Sedation via locus coeruleus → NREM sleep-like EEG → “rousable cooperative sedation” (unique property). NO clinically significant respiratory depression at clinical doses. SEDCOM trial is the landmark ICU evidence. Bradycardia and biphasic BP response are the most common adverse effects; avoid rapid loading boluses.

References: Kamibayashi T, Maze M. Clinical uses of α₂-adrenergic agonists (Anesthesiology 2000;93:1345-1349). Riker RR et al. SEDCOM trial (JAMA 2009;301:489-499). Devlin JW et al. PADIS Guidelines 2018 (Crit Care Med 2018;46:e825-e873). Miller RD et al. Miller's Anaesthesia, 9th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 256 person Asked by .

bookmark_add

Explain the physical principle of infrared absorption spectroscopy [3]. Draw and analyse a normal capnograph waveform, labelling its distinct phases [4]. Describe capnograph variations in bronchospasm, cardiac arrest, and rebreathing [3].

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Long Answer

Capnography — Infrared Spectroscopy, Normal Waveform Phases & Pathological Variations

Explain the physical principle of infrared absorption spectroscopy [3]. Draw and analyse a normal capnograph waveform, labelling its distinct phases [4]. Describe capnograph variations in bronchospasm, cardiac arrest, and rebreathing [3].

⚙ Core Concept

Capnography is a mandatory monitor for all intubated patients under general anaesthesia — it is the most reliable and immediate confirmation of tracheal intubation, provides continuous ventilation monitoring, and acts as a window into cardiovascular physiology. (Bhavani-Shankar K — Anesth Analg; AAGBI Monitoring Standards 2021; Miller's Anaesthesia 9th Ed)

A. Physical Principle — Infrared Absorption Spectroscopy 3 marks

Principle: CO₂ molecules absorb infrared (IR) radiation at specific wavelengths characteristic of molecular bond vibrations; CO₂ absorbs IR maximally at 4.28 µm — the wavelength used in clinical capnographs
Beer-Lambert Law applied: IR absorbed is proportional to CO₂ concentration and path length; capnograph contains an IR source (4.28 µm), a sample cell, and an IR detector — more CO₂ = more absorption = less signal reaching detector
Mainstream vs sidestream: Mainstream — in-line, no sampling delay, heavier, can cause burns; Sidestream — aspirates 50–150 mL/min, slight delay (2–3 s), more common clinically

B. Normal Capnograph Waveform — Four Phases 4 marks

⇗ Waveform Description

Phase	CO₂ Level	Gas Origin	Clinical Significance
Phase I — Inspiratory baseline	0 mmHg (flat, at zero)	Anatomical dead space (no CO₂); inspired fresh gas	Elevated baseline = REBREATHING: exhausted soda lime, incompetent expiratory valve, insufficient FGF in Mapleson D
Phase II — Expiratory upstroke	Rapidly rising from 0 to plateau	Mixing of dead space gas with alveolar gas	Prolonged, gradual slope = V/Q inhomogeneity; seen in bronchospasm
Phase III — Alveolar plateau	Near-flat plateau at ETCO₂ (typically 35–45 mmHg)	Predominantly alveolar gas	Normal: slight upward slope (<2 mmHg); STEEP (“shark fin” >5 mmHg) = bronchospasm/COPD
Phase 0/IV — Inspiratory downstroke	Rapid fall to zero	Fresh inspiratory gas washing out CO₂	ETCO₂ is read at the peak just before this downstroke

Normal ETCO₂: 35–45 mmHg (4.5–6.0 kPa); PaCO₂-ETCO₂ gradient normally 2–5 mmHg; widens with increased dead space (IPPV, Zone 1 expansion, PE, ↓ cardiac output)

C. Pathological Capnograph Variations 3 marks

Condition	Capnograph Pattern	Mechanism
Bronchospasm	“Shark fin”/reverse sawtooth: prolonged gradual Phase II upstroke; steep upward Phase III slope	Inhomogeneous airway resistance; obstructed alveoli empty slowly with higher CO₂ reaching detector later
Cardiac arrest / severe ↓CO	Sudden sustained fall in ETCO₂ to near-zero despite continued ventilation	CO₂ delivery to alveoli requires pulmonary blood flow; no flow → no delivery; ETCO₂ ≥10 mmHg during CPR = adequate compressions
Rebreathing	Elevated baseline (Phase I not at zero)	Exhausted soda lime; incompetent expiratory valve; FGF too low in non-rebreathing system
Oesophageal intubation	Absent or rapidly diminishing waveform — flat within 4–6 breaths	No sustained CO₂ production from stomach; confirms need to remove tube
Pulmonary embolism	Sudden fall in ETCO₂; widened PaCO₂-ETCO₂ gradient	Obstructed pulmonary vessels → ↑ dead space → CO₂ from unperfused regions never delivered to alveoli

💬 Viva Corner

Q. During CPR in theatre, ETCO₂ reads 5 mmHg. What does this tell you and how should it guide your actions?

ETCO₂ 5 mmHg indicates critically inadequate pulmonary blood flow from compressions (benchmark: ≥10 mmHg = adequate). Immediate actions: switch compressor (fatigue is the commonest cause), confirm hand position, depth ≥5 cm, rate 100–120/min, full recoil, minimise pauses. Consider reversible causes (4Hs/4Ts) if compressions are already optimal. Give adrenaline if due. If ETCO₂ stays <10 mmHg after 20 minutes of optimal CPR despite addressing reversible causes, this is associated with failure of ROSC. Conversely, a sudden rise to ≥35 mmHg is the earliest sign of ROSC — stop compressions and check for a pulse.

★ Examiner's Pearl

The waveform must be reproduced as a labelled drawing description with four phases and normal ETCO₂ (35–45 mmHg). The PaCO₂-ETCO₂ gradient (normally 2–5 mmHg; widens with ↑ dead space) is a consistently tested integration question. Shark fin in bronchospasm and the cardiac arrest pattern (sudden fall of ETCO₂ to near-zero) are the two most commonly asked pathological patterns.

References: Bhavani-Shankar K et al. Capnometry and anaesthesia (Can J Anaesth 1992;39:617-632). AAGBI Monitoring Standards 2021. Miller RD et al. Miller's Anaesthesia, 9th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 257 person Asked by .

bookmark_add

Write short notes on: (a) Sugammadex: Mechanism of action, dosing criteria, and limitations [5] (b) Hofmann elimination and ester hydrolysis with reference to Cisatracurium and Remifentanil [5].

description Clinical Response

"

Paper I — Applied Basic Sciences [10 Marks] — Short Notes

Sugammadex & Hofmann Elimination — Mechanism, Dosing, Limitations & Cisatracurium/Remifentanil

Write short notes on: (a) Sugammadex: Mechanism of action, dosing criteria, and limitations [5] (b) Hofmann elimination and ester hydrolysis with reference to Cisatracurium and Remifentanil [5].

A. Sugammadex 5 marks

⚙ Core Concept

Sugammadex (Bridion) is a modified γ-cyclodextrin — a toroidal molecule that forms a tight, 1:1 encapsulation complex with steroidal NMBs (rocuronium > vecuronium > pancuronium), effectively removing free drug from the neuromuscular junction. It is the first truly mechanism-specific NMB reversal agent — unlike neostigmine, which increases ACh at all cholinergic synapses.

Mechanism: hydrophobic interior cavity encapsulates the lipophilic steroid nucleus of rocuronium/vecuronium; Kd for rocuronium ≈ 0.1 µM (extremely tight); complex is pharmacologically INACTIVE and renally excreted intact; as free rocuronium falls, more is drawn from the NMJ down its concentration gradient → reversal
Dosing criteria: 2 mg/kg IV — routine reversal at TOF count ≥2/4 (reversal to TOFR ≥0.9 within 3 min); 4 mg/kg IV — deep block (TOF 0–1, PTC ≥1–2); 16 mg/kg IV — immediate reversal of RSI rocuronium dose (1.2 mg/kg) within 3 minutes
Limitations: does NOT reverse succinylcholine or benzylisoquinolinium NMBs (atracurium, cisatracurium, mivacurium); recurarisation risk if rocuronium re-dosed within 24h; reduces efficacy of progesterone contraceptives (advise additional contraception for 7 days); accumulates in renal failure; expensive; rare anaphylaxis (~1:3500–1:6000)

B. Hofmann Elimination & Ester Hydrolysis 5 marks

⚙ Core Concept

Hofmann elimination and ester hydrolysis are organ-independent chemical degradation pathways — the drug degrades spontaneously in plasma without requiring hepatic metabolism or renal excretion, making these agents safe in organ failure. Cisatracurium and remifentanil are the prime examples.

Hofmann Elimination — Cisatracurium

pH- and temperature-dependent non-enzymatic breakdown at physiological pH (7.4) and 37°C → laudanosine (active CNS stimulant, sub-clinical at normal doses) + monoquaternary acrylate
Cisatracurium is the 1R-cis,1R'-cis isomer of atracurium — 3× more potent (less laudanosine produced); onset 3–5 min; duration 45–60 min
Hepatic/renal failure does NOT prolong its action — ideal for ICU infusions (ARDS, status asthmaticus, ICP management)

Ester Hydrolysis — Remifentanil

Ester linkage hydrolysed by non-specific tissue and blood esterases → remifentanil acid (essentially inactive)
NOT metabolised by plasma pseudocholinesterase — patients with dibucaine-positive pseudocholinesterase deficiency have NORMAL remifentanil metabolism
Context-sensitive half-time (CSHT) = 3 minutes, CONSTANT regardless of infusion duration — because hydrolysis occurs everywhere simultaneously, with no peripheral reservoir

💬 Viva Corner

Q. Why does remifentanil have a constant CSHT of 3 minutes while fentanyl's CSHT rises steeply with infusion duration?

Fentanyl is highly lipophilic and redistributes into peripheral fat during infusion; when stopped, drug slowly returns from fat and requires hepatic metabolism — the longer the infusion, the more accumulation, so CSHT rises steeply (60 min after 1h to 300+ min after 8h). Remifentanil undergoes ester hydrolysis ubiquitously throughout the body, including peripheral compartments — there is no reservoir slowly releasing drug back into plasma. The drug disappears from all compartments simultaneously, so CSHT stays constant at 3 minutes regardless of duration. Clinically, long-acting analgesia must be established before stopping remifentanil, as its analgesic effect disappears within 5–10 minutes.

★ Examiner's Pearl

Sugammadex doses must be exact: 2 mg/kg (TOF ≥2); 4 mg/kg (PTC ≥1, TOF 0); 16 mg/kg (immediate reversal post-RSI). Does NOT work for succinylcholine or atracurium — steroidal NMBs ONLY. Remifentanil ester hydrolysis by NON-SPECIFIC esterases (NOT pseudocholinesterase) is the specific frequently-tested distinction.

References: Naguib M. Sugammadex (Anesthesiology 2007;106:1267-1273). Papazian L et al. Neuromuscular blockers in early ARDS (NEJM 2010;363:1107-1116). Minto CF et al. Remifentanil pharmacokinetics (Anesthesiology 1997;86:10-23). Miller RD et al. Miller's Anaesthesia, 9th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 258 person Asked by .

bookmark_add

Describe the anatomy of the NMJ. Discuss normal physiology. Describe depolarising and non-depolarising muscle relaxants. Discuss tests for neuromuscular block monitoring.

description Clinical Response

"

⚙ CORE CONCEPT

The Neuromuscular Junction (NMJ) is the specialised synapse between the motor nerve terminal and skeletal muscle fibre — a site of remarkable pharmacological specificity where anaesthesiologists exert precise control over muscle relaxation. Every muscle relaxant, reversal agent, and monitoring technique is designed around this junction's anatomy and physiology. Understanding the NMJ is the foundation of safe paralysis in anaesthesia practice.

(Naguib M — NMJ review NEJM; Bowman WC — pharmacology of NMB; Donati F — neuromuscular pharmacology; Fuchs-Buder T — monitoring NMB)

A. Anatomy of the Neuromuscular Junction

△ NMJ STRUCTURE — DETAILED DIAGRAM

MOTOR NEURON AXON
  | (myelinated)
  |
+----v----------------------------------------------+
| MOTOR NERVE TERMINAL (bouton)                      |
| +-------------------------------------------------+ |
| | ACh VESICLES: ~10,000 vesicles per terminal      | |
| | Each vesicle: ~5,000-10,000 ACh molecules (1 quantum)| |
| | ACTIVE ZONES: docked vesicles ready for release  | |
| | Voltage-gated Ca2+ channels (P/Q-type) at active zones| |
| | Mitochondria: ATP for ACh synthesis              | |
| +-------------------------------------------------+ |
+---------------------+-------------------------------+
                       | SYNAPTIC CLEFT (~50 nm)
                       | Acetylcholinesterase (AChE)
                       | Collagen fibrils
                       | Agrin protein (organises postjxn)
+----------------------v-----------------------------+
| POSTJUNCTIONAL MEMBRANE (Motor End Plate)           |
| JUNCTIONAL FOLDS: deep infoldings ^ surface area ~10x|
| nAChRs densely packed at CRESTS of junctional folds |
| AChE located at DEPTHS of folds                     |
| nAChR density: ~10,000-20,000 per um2 at the crests |
|                                                       |
| nAChR STRUCTURE (pentameric):                        |
| a1 (x2) + b1 + d + e (adult) or g (fetal/extrajxnal) |
| ACh binding site on EACH a1 subunit                  |
| BOTH a1 subunits must be occupied for channel opening|
+-------------------------------------------------------+

PREJUNCTIONAL RECEPTORS: a3b2 nAChRs (autoreceptors)
-> POSITIVE FEEDBACK: ACh released -> binds prejxnal receptors
-> Facilitates further ACh release (mobilisation during tetanus)
Non-depolarising NMBDs block BOTH pre- and postjunctional receptors
-> Explains ""fade"" on sustained/tetanic stimulation

Component	Details
ACh Synthesis and Storage	Synthesised in the nerve terminal from CHOLINE (taken up by Na⁺-dependent high-affinity choline transporter) + ACETYL-CoA (from mitochondrial pyruvate metabolism); enzyme: CHOLINE ACETYLTRANSFERASE (ChAT); stored in synaptic vesicles (~10,000 molecules = 1 quantum); SPONTANEOUS release of individual quanta = miniature end-plate potentials (MEPPs) — basis of the "safety factor"
Presynaptic voltage-gated Ca²⁺ channels	P/Q-type (CaV2.1) calcium channels at active zones; action potential → membrane depolarisation → Ca²⁺ influx → triggers vesicle fusion (SNARE protein complex: synaptobrevin, SNAP-25, syntaxin) → EXOCYTOSIS of ACh quanta; ~60–100 quanta released per action potential (quantum content); Lambert-Eaton myasthenic syndrome targets these channels
Acetylcholinesterase (AChE)	Located at the DEPTHS of junctional folds; collagen-tailed tetramers (A₁₂ form); hydrolyses ACh → CHOLINE + ACETATE within 1 millisecond; remarkably efficient — one enzyme molecule can hydrolyse 25,000 ACh molecules per second; choline is recycled back into the nerve terminal; inhibited by: neostigmine, pyridostigmine (reversible carbamate inhibitors), organophosphates (irreversible)
nAChR Structure and Function	NICOTINIC ACETYLCHOLINE RECEPTOR: pentameric ligand-gated ion channel (2α₁ + β₁ + δ + ε in adult; γ replaces ε in fetal/denervated/extrajunctional); ion channel is non-selective cation channel (Na⁺ in, K⁺ out); BOTH α₁ subunits must be occupied by ACh (or agonist) for channel opening; opens for ~1 ms → ion flow → END-PLATE POTENTIAL (EPP); EPP must reach threshold → action potential propagates along muscle fibre → contraction; EXTRAJUNCTIONAL RECEPTORS (γ-subunit): appear with denervation, immobility, burns → increased K⁺ release with suxamethonium → hyperkalaemia risk

B. Normal Physiology and Functions of the NMJ

Physiological Process	Detail
Normal Neuromuscular Transmission (Step-by-Step)	(1) Action potential propagates down motor axon to nerve terminal; (2) Depolarisation → P/Q-type Ca²⁺ channels open → Ca²⁺ influx; (3) Ca²⁺ triggers SNARE-mediated exocytosis of ~60–100 ACh quanta; (4) ACh diffuses across 50 nm synaptic cleft; (5) ACh binds BOTH α₁ subunits of nAChR → ion channel opens; (6) Na⁺ influx (+ K⁺ efflux) → END-PLATE POTENTIAL (EPP) +25 to +40 mV; (7) EPP spreads to adjacent muscle membrane → exceeds threshold → action potential in muscle fibre; (8) Muscle action potential propagates along T-tubules → Ca²⁺ release from SR → actin-myosin crossbridge cycling → CONTRACTION; (9) AChE hydrolyses ACh → choline recycled → termination of signal
Safety Factor of NMJ	The EPP generated by normal neuromuscular transmission is MUCH LARGER than required to trigger muscle action potential — a "margin of safety" approximately 3–4×; this safety factor means that even with partial nAChR blockade (~75–80%), sufficient receptors remain to generate adequate EPP for contraction; clinical weakness (force <25% of normal) is not detectable by clinical examination until 70–80% of receptors are blocked; critically: PORC (post-operative residual curarisation) = TOF ratio <0.9 — patient can fail clinical tests of strength but still be unable to maintain airway at TOF ratio 0.7–0.9
Tetanic Stimulation and Post-Tetanic Potentiation	HIGH-FREQUENCY stimulation (≥50 Hz = tetanus): initially ↑ quantal ACh release (facilitation — mobilisation from reserve pool); maintained tetanus → depletion of immediately available quanta → FADE (↓ force over time); POST-TETANIC POTENTIATION (PTP/PTC): after tetanus ends, residual Ca²⁺ in terminal → ↑ baseline ACh release for 2–4 minutes → allows transmission at some blocked NMJs → post-tetanic count (PTC) reveals response even when TOF count is 0
Fade — the basis of NMJ monitoring	NON-DEPOLARISING NMBDs block PREJUNCTIONAL α₃β₂ receptors → prevents ACh mobilisation during high-frequency stimulation → FADE (ratio of 4th to 1st twitch = TOF ratio <1.0); DEPOLARISING NMBDs do NOT cause fade (equal depression of all twitches — a "Phase 1 block"); fade detection = basis of TOF and tetanic stimulation monitoring

C. Non-Depolarising Muscle Relaxants (NDNMBDs)

Drug	Onset	Duration	Dose (intubation)	Metabolism/Excretion	Key Features
Atracurium (Benzylisoquinolinium)	Intermediate onset (2–3 min)	Intermediate (20–35 min)	0.5 mg/kg	HOFMANN ELIMINATION (pH + temp dependent, organ-independent) + ester hydrolysis; metabolite: laudanosine (CNS stimulant — seizures at high plasma levels; clinically insignificant at usual doses)	IDEAL for renal/hepatic failure; HISTAMINE RELEASE (intrinsic, dose-dependent); inject slowly; no cardiovascular effect at clinical doses
Cisatracurium (Benzylisoquinolinium)	Intermediate onset (2–3 min)	Intermediate (40–60 min)	0.15 mg/kg	HOFMANN ELIMINATION only (no ester hydrolysis); laudanosine produced in smaller amounts	CLEANER than atracurium — NO histamine release; organ-independent elimination; preferred in ICU; more expensive
Mivacurium (Benzylisoquinolinium)	Short onset (2–3 min)	SHORT (12–20 min)	0.2 mg/kg	PLASMA CHOLINESTERASE (pseudocholinesterase) — same enzyme as suxamethonium; organ-independent	SHORTEST acting NDNMBD; prolonged in pseudocholinesterase deficiency; histamine release
Rocuronium (Steroidal)	RAPID onset (60–90s at 0.6 mg/kg; 30s at 1.2 mg/kg)	Intermediate (30–60 min)	0.6 mg/kg (routine); 1.2 mg/kg (RSI)	HEPATIC metabolism + biliary excretion; RENAL (10–25%); prolonged in liver disease	FASTEST onset of NDNMBDs; ONLY NDNMBD suitable for RSI; REVERSIBLE with SUGAMMADEX (16 mg/kg — CICO rescue)
Vecuronium (Steroidal)	Intermediate onset (2–3 min)	Intermediate (25–40 min)	0.1 mg/kg	HEPATIC (80%), renal (20%); active metabolite 3-OH vecuronium accumulates in renal failure	NO histamine; NO cardiovascular effects (no vagolytic); AVOID in hepatic failure; reversed by sugammadex or neostigmine
Pancuronium (Steroidal)	Slow onset (3–5 min)	LONG (60–120 min)	0.1 mg/kg	RENAL (80%); hepatic (20%); AVOID in renal failure	VAGOLYTIC (tachycardia, ↑BP); used for ICU paralysis and cardiac surgery; reversed by neostigmine

D. Depolarising Muscle Relaxants

Feature	Detail
Drug: SUXAMETHONIUM (Succinylcholine)	The ONLY clinically used depolarising NMBD; two acetylcholine molecules joined at their acetyl groups (bis-quaternary ammonium compound); dose: 1–1.5 mg/kg IV (RSI); onset: 30–45 seconds; duration: 8–12 min (shortest-acting NMBD); metabolised by PSEUDOCHOLINESTERASE in plasma and liver → succinylmonocholine → succinic acid + choline
Mechanism — Phase 1 (Depolarising) Block	Sch acts as an ACh AGONIST — binds BOTH α₁ subunits of nAChR → opens ion channel → SUSTAINED depolarisation; NOT hydrolysed by AChE → remains bound → end plate stays depolarised → adjacent Na⁺ channels inactivated → FLACCID PARALYSIS; initial fasciculations then flaccid block; no fade on TOF or tetanus; PTC normal; abolished by pseudocholinesterase
Phase 2 (Desensitisation) Block	With LARGE or REPEATED doses of Sch: nAChRs become DESENSITISED; block now shows FADE on TOF (mimics NDNMBD); prolonged and potentially irreversible; occurs with total Sch dose >5–6 mg/kg or prolonged infusion
ADVERSE EFFECTS	HYPERKALAEMIA: plasma K⁺ rises 0.5–1.0 mEq/L normally; DANGEROUS in burns (>24h), denervation, prolonged immobility, crush injury, rhabdomyolysis, muscular dystrophies — K⁺ rise 5–10 mEq/L → fatal cardiac arrest. BRADYCARDIA: muscarinic (M2) stimulation, especially second dose or in children. MALIGNANT HYPERTHERMIA TRIGGER: treat with dantrolene 2.5 mg/kg IV. MYALGIA: prevented by defasciculation (vecuronium 0.01 mg/kg or rocuronium 0.06 mg/kg 90 sec before Sch). RAISED ICP, IOP, INTRAGASTRIC PRESSURE. PROLONGED BLOCK (Suxamethonium apnoea): pseudocholinesterase deficiency (dibucaine number <30 = homozygous atypical).
INDICATIONS	RAPID SEQUENCE INTUBATION (RSI) — fastest onset + shortest duration; LARYNGOSPASM treatment (0.5 mg/kg IV or 4 mg/kg IM)

Mechanism of NDNMBDs: COMPETITIVE ANTAGONISM at BOTH α₁ subunits of postjunctional nAChR — they BIND the receptor without activating the ion channel; ACh is DISPLACED or prevented from occupying both sites; ALSO block PREJUNCTIONAL α₃β₂ receptors → prevent ACh mobilisation → FADE; the blockade is REVERSIBLE. REVERSAL: neostigmine (+ glycopyrrolate) inhibits AChE; SUGAMMADEX encapsulates rocuronium/vecuronium directly.

Factors affecting NDNMBD action: potentiation by volatile anaesthetics, hypokalaemia, hypermagnesaemia, hypothermia, aminoglycosides, respiratory acidosis; RESISTANCE with chronic phenytoin/carbamazepine, denervation.

E. Tests for Neuromuscular Block Monitoring

△ NMJ MONITORING — SITES AND PATTERNS

STIMULATION SITES (peripheral nerve stimulation):
- ULNAR NERVE at wrist (most common) -> adductor pollicis (thumb adduction)
- FACIAL NERVE (orbicularis oculi/corrugator) -- poor indicator of diaphragm/laryngeal recovery
- Posterior tibial nerve -> flexor hallucis brevis
- Common peroneal nerve -> extensor hallucis longus

RESPONSE MEASUREMENT:
- CLINICAL observation (least accurate)
- MECHANOMYOGRAPHY (MMG) -- gold standard but cumbersome
- ACCELEROMYOGRAPHY (AMG) -- most common clinical method (TOF-Watch SX)
  AMG TOF ratio >0.9 = adequate recovery (may overestimate)
- ELECTROMYOGRAPHY (EMG) -- measures muscle electrical activity directly
- KINEMYOGRAPHY (KMG) -- measures movement

Monitoring Test	Stimulation Pattern	Interpretation	Depth of Block Detected
Single Twitch (ST)	Single supramaximal stimulus (0.1–0.2 ms); 0.1 Hz	Height of twitch as % of control; 75–80% receptor blockade before visible twitch depression	GROSS measure only; insensitive to early block; not useful clinically without control value
Train-of-Four (TOF)	4 supramaximal stimuli at 2 Hz; every 10–12 sec; TOF RATIO = T4/T1	TOF COUNT: 0 = profound; 1 = deep; 2 = moderate; 3–4 = light block; TOF RATIO ≥0.9 = adequate recovery	MOST USEFUL single monitoring test; TOF ratio <0.9 = PORC risk; FADE distinguishes NDNMBD from depolarising block
Tetanic Stimulation	50 Hz for 5 sec; 100 Hz if very deep block suspected	SUSTAINED = adequate function; FADE = residual NDNMBD block	Very sensitive for RESIDUAL block; PAINFUL — not for routine intraoperative use
Post-Tetanic Count (PTC)	50 Hz tetanic x 5 sec → 3 sec pause → single 1 Hz twitches counted	PTC 1–2 = very deep; PTC 5–6 = TOF response in ~10 min; PTC >10 = TOF response imminent	Detects PROFOUND BLOCK when TOF count = 0
Double Burst Stimulation (DBS)	2 short tetanic bursts (3 stimuli at 50 Hz, 750 ms apart): DBS3,3	Second burst smaller = FADE = residual block; equal = adequate recovery	Detects RESIDUAL BLOCK when TOF ratio cannot be quantified

F. PORC — Post-Operative Residual Curarisation

Aspect	Key Points
Definition	TOF ratio <0.9 at tracheal extubation or in PACU; incidence up to 40–50% when reversal not used; associated with airway obstruction, hypoxaemia, aspiration pneumonia, muscle weakness, impaired hypoxic ventilatory response
Clinical tests (unreliable for TOF <0.9)	5-second head lift: can be performed at TOF ratio 0.5 (UNRELIABLE); sustained hand grip; tongue depressor test; vital capacity <15 mL/kg; sustained tetanus (more sensitive but painful); QUANTITATIVE monitoring is the only reliable method
Prevention	QUANTITATIVE NMJ monitoring (AMG/EMG) MANDATORY for every case using NDNMBD; SUGAMMADEX for rocuronium/vecuronium — most reliable reversal; neostigmine (ceiling effect); avoid extubation until TOF ratio ≥0.9 confirmed quantitatively

💬 VIVA CORNER

Why do we use TOF ratio >0.9 and not 1.0 as the target for extubation?
A TOF ratio of 1.0 is the physiological ideal, but TOF ratio ≥0.9 correlates with clinically adequate neuromuscular recovery — patients can protect their airway, maintain oxygen saturation, and perform reliable clinical tests. Below 0.9, significant impairment of pharyngeal and laryngeal muscle function occurs. Routine CLINICAL TESTS can be performed successfully at TOF ratio as low as 0.5 — they are UNRELIABLE. Only QUANTITATIVE monitoring can reliably confirm TOF ≥0.9, which is why NAP5 and current guidelines mandate it.

Why is suxamethonium absolutely contraindicated in burns patients but only relatively contraindicated in the first 24 hours?
In the FIRST 24 HOURS after burn injury, extrajunctional acetylcholine receptor proliferation has not yet occurred (takes 24–72h). So in the first 24h, suxamethonium causes only the normal 0.5–1.0 mEq/L rise in plasma K⁺. AFTER 24 HOURS, millions of extrajunctional receptors are expressed — depolarising all simultaneously causes massive K⁺ efflux (5–10 mEq/L) → VF → cardiac arrest. This risk persists indefinitely; the same applies to denervation, prolonged immobility, and severe sepsis.

★ EXAMINER'S PEARL

NMJ ANATOMY: Motor nerve terminal (vesicles, P/Q Ca²⁺ channels, active zones) → 50nm synaptic cleft (AChE at fold depths) → postjunctional membrane (junctional folds, nAChRs at crests: α₁₂β₁δε pentamer). PHYSIOLOGY: AP → Ca²⁺ → 60-100 quanta released → ACh binds BOTH α₁ → ion channel opens → EPP → muscle AP → contraction. SAFETY FACTOR: EPP 3-4x threshold needed; 75-80% receptors must be blocked before twitch depresses. NDNMBDs: COMPETITIVE ANTAGONIST at both α₁ (postjunctional) + prejunctional block → FADE on TOF. Rocuronium (RSI at 1.2 mg/kg, 30 sec); atracurium/cisatracurium (Hofmann — renal/hepatic failure). Suxamethonium: agonist → sustained depolarisation → flaccid block; AVOID: burns >24h, denervation, MH susceptibility, hyperkalaemia, open globe; PHASE 2 block with large doses (shows fade). MONITORING: TOF most important (count + ratio); PTC for profound block (count 0); DBS most sensitive clinical fade detection; QUANTITATIVE monitoring (AMG/EMG) mandatory → TOF ≥0.9 for extubation. PORC: TOF <0.9 — incidence 40-50% without monitoring; head lift unreliable (positive at TOF 0.5).

References: Naguib M et al. Advances in NMJ pharmacology. Anesthesiology 2002;96:202-231. Bowman WC. Neuromuscular block. Br J Pharmacol 2006;147:S277-286. Murphy GS et al. Residual NMB. Anesth Analg 2015;121:1329-1335.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 259 person Asked by .

bookmark_add

Discuss in detail the anatomy of the brachial plexus. Enumerate and describe various blocks used to block the brachial plexus at various levels.

collections Question Diagrams & Reference Images (2)

zoom_in View Image

description Clinical Response

"

⚙ CORE CONCEPT

The brachial plexus is the neural network supplying the entire upper limb — formed by the ventral rami of C5–T1 with variable contributions from C4 and T2. Understanding its anatomy — from the interscalene groove to the axilla — is the prerequisite for selecting the correct block for each surgical site, and for avoiding the complications (pneumothorax, intravascular injection, phrenic nerve palsy, Horner syndrome) that differ between approaches. Ultrasound guidance has transformed brachial plexus block from a landmark technique into a direct-visualisation procedure.

(Gray's Anatomy; Neal JM — brachial plexus blocks; Chin KJ — ultrasound-guided regional anaesthesia; Urmey WF — interscalene block; Borene SC — axillary block; Raj P — practical management of pain)

A. Anatomy of the Brachial Plexus

△ BRACHIAL PLEXUS — COMPLETE ANATOMICAL DIAGRAM

NERVE ROOTS (C5-T1) -> TRUNKS -> DIVISIONS (ant/post) -> CORDS -> TERMINAL BRANCHES

C4 (variable) -+
C5 ------------+
               +-- UPPER TRUNK --+-- Anterior ------------------------>
C6 ------------+                 +-- Posterior ----------+
C7 ------------  MIDDLE TRUNK --+-- Anterior ------+     |  POSTERIOR CORD
                                 +-- Posterior -----+     +-- Axillary N. (C5,C6)
C8 ------------+                                     |    +-- Radial N. (C5-T1)
               +-- LOWER TRUNK --+-- Anterior -------+    +-- Thoracodorsal N.
T1 ------------+                 +-- Posterior ------+
T2 (variable) -+                                  MEDIAL CORD
                                                   +-- Ulnar N. (C8,T1)
- Upper trunk (C5,C6): Suprascapular N.           +-- Medial cutaneous N. arm
  + Nerve to subclavius                           +-- Medial cutaneous N. forearm
- All three trunks: anterior divisions -> LATERAL
  and MEDIAL cords; posterior divisions -> POSTERIOR CORD   LATERAL CORD
                                                   +-- Musculocutaneous N. (C5,6,7)
LATERAL CORD (C5,6,7) + MEDIAL CORD (C8,T1) -> MEDIAN NERVE  +-- Lateral root of median N.

LOCATION SEQUENCE (IMPORTANT FOR BLOCKS):
Interscalene groove -> Between anterior and middle scalene muscles
Supraclavicular -> Over 1st rib, behind clavicle, ""corner pocket""
Infraclavicular -> Below clavicle, lateral to coracoid process
Axillary -> Axilla, around axillary artery

ANATOMICAL RELATIONSHIPS AT EACH LEVEL:
Interscalene: TRUNKS; C6 level; surrounded by interscalene fascia
Supraclavicular: DIVISIONS/TRUNKS; superficial, compact, ""corner pocket""
Infraclavicular: CORDS; around axillary artery (posterior, lateral, medial)
Axillary: TERMINAL BRANCHES; within axillary sheath

Level	Structure	Nerve Roots	Key Branches	Clinical Supply
ROOTS (C5–T1)	Ventral rami exit intervertebral foramina; groove between anterior and posterior scalene tubercles; PREVERTEBRAL FASCIA covers them	C5, C6, C7, C8, T1; C4 and T2 variable contributions	Dorsal scapular N. (C5); Long thoracic N. (C5,6,7); phrenic N. arises from C4 with contributions C3,C5	At root level — deepest and most proximal approach; PARAVERTEBRAL approach targets roots
TRUNKS (3)	Upper (C5+C6), Middle (C7), Lower (C8+T1); posterior triangle of neck between anterior and middle scalene muscles; INTERSCALENE GROOVE	Upper = C5,C6; Middle = C7; Lower = C8,T1	Upper trunk: suprascapular nerve; nerve to subclavius; Upper trunk = ERB'S POINT at C6 level	INTERSCALENE BLOCK targets trunks; excellent for shoulder surgery
DIVISIONS (6)	Each trunk divides into anterior (flexor) and posterior (extensor) division; pass BEHIND clavicle to enter axilla; SUPRACLAVICULAR level — compact, superficial, on 1st rib	Anterior divisions → lateral + medial cords; Posterior divisions → posterior cord	No named branches at division level	SUPRACLAVICULAR BLOCK targets divisions — most complete upper limb block
CORDS (3)	Posterior cord (all posterior divisions); Lateral cord (anterior div of upper+middle trunk); Medial cord (anterior div of lower trunk); named by relationship to AXILLARY ARTERY; INFRACLAVICULAR	Posterior = C5–T1; Lateral = C5,6,7; Medial = C8,T1	Posterior cord: axillary N. + radial N. + thoracodorsal N.; Lateral cord: musculocutaneous N. + lateral root of median; Medial cord: ulnar N. + medial roots of median + medial cutaneous nerves	INFRACLAVICULAR BLOCK targets cords — excellent for elbow, forearm, hand; avoids phrenic nerve palsy
TERMINAL BRANCHES (5)	Musculocutaneous N., Median N., Ulnar N., Radial N., Axillary N.	As above	Plus: medial cutaneous N. arm+forearm from medial cord	AXILLARY BLOCK targets terminal branches — safe (no pneumothorax); musculocutaneous often leaves the sheath early → must be blocked separately

B. Brachial Plexus Blocks — Approach-by-Approach

Block	Level	Technique (US-guided)	LA Dose	Indications	Complications
INTERSCALENE BLOCK (ISB)	TRUNKS at C5–C6 level; between anterior and middle scalene	Patient supine, head rotated away; identify SCM, then scalene muscles; trunks visible as 3 hypoechoic nodules ("traffic light") between scalenes; in-plane needle from posterior	20 mL 0.5% ropivacaine or 0.5% bupivacaine	SHOULDER SURGERY (best block); clavicle surgery; proximal humerus; NOT suitable for hand surgery alone	PHRENIC NERVE PALSY (100% incidence); Horner syndrome; intravascular injection into vertebral artery; pneumothorax (rare); recurrent laryngeal nerve palsy
SUPRACLAVICULAR BLOCK (SCB)	TRUNKS/DIVISIONS at supraclavicular fossa ("corner pocket of the body")	Identify subclavian artery above 1st rib; plexus = hypoechoic nodules lateral/superficial to artery ("honeycomb"); 25–30 mL deposited in "corner pocket"	25–30 mL 0.5% ropivacaine or 0.375% bupivacaine	ENTIRE UPPER LIMB distal to shoulder — most complete single-injection block	PNEUMOTHORAX (0.5–6% landmark; <0.5% US); phrenic nerve palsy (60–80%); Horner syndrome; intravascular injection
INFRACLAVICULAR BLOCK (ICB)	CORDS; below clavicle at coracoid; cords around axillary artery	Identify axillary artery/vein below clavicle; cords as hyperechoic nodules around artery; single injection behind artery	30 mL 0.5% ropivacaine	ENTIRE UPPER LIMB incl. hand; forearm and hand surgery; avoids phrenic nerve palsy; catheter placement easy	Pneumothorax (rare); intravascular injection; injury to axillary vessels; failure to block musculocutaneous nerve
AXILLARY BLOCK (AB)	TERMINAL BRANCHES in axillary sheath; medial upper arm	Arm abducted 90°, externally rotated; identify axillary artery; nerves around artery (median superficial/lateral, ulnar medial, radial posterior, musculocutaneous separate)	5–10 mL per nerve (total 30–40 mL); 0.375–0.5% ropivacaine	FOREARM and HAND surgery; SAFEST approach; suitable in anticoagulated patients	MUSCULOCUTANEOUS NERVE MISS (most common failure); intravascular injection; haematoma (compressible)
CERVICAL PARAVERTEBRAL BLOCK	NERVE ROOTS at cervical foramina	US-guided at C5–C7 transverse process level; deepest approach	3–5 mL per level	Shoulder; neck surgery; rarely used	HIGHEST RISK of serious complications: epidural/intrathecal injection, intravascular injection, phrenic nerve palsy; NOT recommended for routine use
SUPRASCAPULAR NERVE BLOCK	Branch of upper trunk; suprascapular notch (posterior shoulder)	Identify scapular spine, suprascapular notch, artery; 5–10 mL LA at notch	5–10 mL 0.5% ropivacaine	SHOULDER PAIN and ROTATOR CUFF SURGERY — covers 70% of shoulder joint innervation; useful adjunct to ISB, avoids phrenic palsy	Pneumothorax (rare); intravascular; nerve injury (rare)

C. Cutaneous Innervation Summary — Selecting the Right Block

Surgery Site	Best Block	Alternative
Shoulder (glenohumeral joint, rotator cuff)	INTERSCALENE BLOCK	Suprascapular + axillary nerve block (avoids phrenic palsy)
Clavicle fracture	Interscalene (+ superficial cervical plexus block for medial clavicle)	Supraclavicular
Entire arm including hand	SUPRACLAVICULAR BLOCK (most complete single injection)	Infraclavicular
Elbow and forearm	Supraclavicular or Infraclavicular	Axillary (high volume)
Hand and wrist	AXILLARY BLOCK (safest) or Infraclavicular	Wrist block for minor procedures
Patient with severe respiratory disease (avoid phrenic palsy)	INFRACLAVICULAR or AXILLARY block	Suprascapular + axillary nerve for shoulder

★ EXAMINER'S PEARL

Brachial plexus: ROOTS (C5-T1) → 3 TRUNKS (upper C5+6, middle C7, lower C8+T1) → 6 DIVISIONS (ant+post each) → 3 CORDS (named by axillary artery relationship: lateral, medial, posterior) → 5 TERMINAL BRANCHES (musculocutaneous, median, ulnar, radial, axillary). Mnemonic: "Robert Taylor Drinks Cold Beer." Blocks: INTERSCALENE (trunks, shoulder surgery — 100% phrenic palsy → CONTRAINDICATED in contralateral phrenic palsy); SUPRACLAVICULAR (divisions, "corner pocket," most complete for whole arm, pneumothorax risk); INFRACLAVICULAR (cords around axillary artery, no phrenic palsy risk, good for forearm/hand, catheter placement easy); AXILLARY (terminal branches, SAFEST, no pneumothorax/phrenic palsy, musculocutaneous MUST be blocked separately in coracobrachialis). US guidance = standard of care. Intercostobrachial nerve (T2) = tourniquet pain → always block subcutaneously for arm tourniquet procedures.

References: Neal JM et al. ASRA Practice Advisory on Neurologic Complications in Regional Anesthesia. Reg Anesth Pain Med 2015. Chin KJ, Perlas A. Ultrasonography of the brachial plexus. Anesthesiology 2011. Gray's Anatomy, 41st Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 260 person Asked by .

bookmark_add

Define ICP and CPP. Discuss CSF circulation in detail. Discuss the various methods used in OT and ICU to manage raised ICP. What are the features of raised ICP?

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

"

⚙ CORE CONCEPT

The intracranial compartment is a fixed, rigid vault — the MONRO-KELLIE DOCTRINE states that the total intracranial volume (brain + CSF + blood) is constant; any increase in one component must be compensated by a decrease in another, or intracranial pressure (ICP) will rise. When compensatory mechanisms are exhausted, even small volume additions cause dramatic ICP rises — the "exponential compliance curve." Management of raised ICP is one of the most common and critical challenges in both neurological ICU and neuroanaesthesia.

(Miller RD — Miller's Anaesthesia; Czosnyka M — ICP monitoring review; BTIF TBI guidelines 2023; Rasulo FA — ICP management; Rangel-Castilla L — ICP management)

1. Definitions

Term	Definition	Normal Values	Significance
ICP (Intracranial Pressure)	The pressure exerted by the contents of the cranial vault (brain parenchyma 80% + CSF 10% + blood 10%) within the rigid skull; measured in mmHg; represents pressure gradient between intracranial contents and atmospheric pressure (transducer zeroed at foramen of Monro)	NORMAL: 5–15 mmHg (adults supine); 0–7 mmHg (seated); 1.5–6 mmHg (children); <2 mmHg (neonates); RAISED: >20 mmHg sustained; SEVERE: >40 mmHg critical; >60 mmHg near-fatal	Sustained ICP >20 mmHg = worse neurological outcomes; treatment threshold: ICP >20–22 mmHg (BTF 2016); ICP >40 mmHg = cerebral perfusion critically compromised
CPP (Cerebral Perfusion Pressure)	The pressure gradient driving cerebral blood flow; CPP = MAP − ICP (or MAP − CVP if CVP > ICP); AUTOREGULATION maintains CBF constant over CPP range 50–150 mmHg; PRESSURE-PASSIVE when autoregulation fails	NORMAL: 60–80 mmHg; MINIMUM: ≥60 mmHg (adult TBI — BTF); >70 mmHg preferred; PAEDIATRIC: ≥40–50 mmHg; CPP <50 mmHg = cerebral ischaemia likely; CPP <30 mmHg = irreversible injury imminent	CPP is the THERAPEUTIC TARGET in neuroanaesthesia — not just ICP alone; CPP 60–70 mmHg target in TBI (BTF 2016); CPP-guided therapy has replaced purely ICP-guided therapy

2. Monro-Kellie Doctrine and Compliance

△ INTRACRANIAL COMPLIANCE CURVE

ICP ^      ,---- DECOMPENSATED PHASE
(mmHg)|    /  (steep: small vol increase = large ICP increase)
 40 --|   /  <- Treatment threshold 20-22 mmHg
      |  /
 20 --|-------------,---'  <- Inflection point (compensation exhausted)
      |      ,------'   COMPENSATED PHASE (flat: CSF + venous displaced)
  5 --|------'  Normal ICP range
      +--------------------------------------------> INTRACRANIAL VOLUME UP

COMPENSATORY MECHANISMS (operate on the flat part of curve):
1. CSF DISPLACEMENT: CSF pushed from cranial to spinal compartment (up to 50 mL)
2. VENOUS BLOOD DISPLACEMENT: cerebral venous blood squeezed into dural sinuses
   and jugular veins (up to 50-75 mL)
3. Once these are exhausted -> EXPONENTIAL ICP RISE (vertical part of curve)
   -> HERNIATION syndromes begin

3. CSF Circulation — Complete Description

Component	Detail
CSF Production	CHOROID PLEXUS (70% of CSF): specialised ependymal cells lining lateral, 3rd, and 4th ventricles; Na⁺-K⁺-ATPase drives Na⁺ into CSF → water follows osmotically; CSF formation rate: 0.35 mL/min = 500 mL/day; total CSF volume: 150 mL (50 mL intracranial + 100 mL spinal); REPLACED 3–4 TIMES/DAY; also brain parenchyma (30%); production PRESSURE-INDEPENDENT (largely); CARBONIC ANHYDRASE essential → ACETAZOLAMIDE inhibits CSF production
CSF Composition	Clear, colourless; protein: 15–45 mg/dL; glucose: 2.5–4.5 mmol/L (60–80% of plasma, ratio >0.6 normal); sodium: 135–150 mEq/L; cells: WBC <5/mm³; pressure: 8–18 cmH₂O (lateral decubitus) = 6–13 mmHg; pH 7.32–7.35
CSF Circulation Pathway	LATERAL VENTRICLES (choroid plexus) → FORAMINA OF MONRO → 3rd VENTRICLE → CEREBRAL AQUEDUCT OF SYLVIUS (most common obstruction site) → 4th VENTRICLE → FORAMINA OF LUSCHKA (×2) and MAGENDIE (×1) → SUBARACHNOID SPACE (basal cisterns) → ascends over cerebral hemispheres (pulsatile bulk flow) → DURAL VENOUS SINUSES via ARACHNOID GRANULATIONS → reabsorbed into venous blood → jugular veins → SVC
Arachnoid Granulations (reabsorption)	Herniations of arachnoid membrane into dural venous sinuses (mainly superior sagittal sinus); pressure-dependent VALVES — open when ICP exceeds venous sinus pressure (by 5–7 mmHg); MALABSORPTION = COMMUNICATING HYDROCEPHALUS; OBSTRUCTION at aqueduct/foramina = OBSTRUCTIVE (NON-COMMUNICATING) HYDROCEPHALUS
Pulsatile CSF Flow	Driven by cardiac cycle (systolic pulsations → CSF pushed into spinal canal) and respiratory cycle (inspiration → ↓ intrathoracic pressure → ↑ epidural venous engorgement → CSF pushed rostrally); phase-contrast MRI visualises this (important in Chiari malformation)

4. Features of Raised ICP

Feature	Mechanism	Clinical Significance
HEADACHE (early, classic)	Distension of pain-sensitive intracranial structures; worse in morning (↑ ICP during recumbency + REM sleep); exacerbated by Valsalva	Bilateral, frontal/occipital; "bursting" quality; morning headache waking patient = RED FLAG
VOMITING (projectile)	Stimulation of vomiting centre in medulla; characteristic PROJECTILE pattern without preceding nausea	Unexplained projectile vomiting with headache = raised ICP until proven otherwise
PAPILLOEDEMA	ICP transmitted along optic nerve sheath → impaired axoplasmic flow → axonal swelling at optic disc; TAKES 24–48H TO DEVELOP	BILATERAL papilloedema = raised ICP until proven otherwise; loss of venous pulsation = earliest sign
CUSHING'S TRIAD / REFLEX (late, critical)	ICP approaches MAP → brainstem ischaemia → medullary vasomotor centre ischaemia → SYSTEMIC HYPERTENSION (compensatory) → baroreceptor BRADYCARDIA; medullary compression → IRREGULAR BREATHING	HYPERTENSION + BRADYCARDIA + IRREGULAR RESPIRATION = PRE-TERMINAL sign of impending herniation; do NOT treat hypertension with antihypertensives
ALTERED CONSCIOUSNESS / GCS DECLINE	Diffuse cortical dysfunction; RAS compression in midbrain → loss of consciousness	Deteriorating GCS = raised ICP until proven otherwise (urgent CT); GCS ≤8 = severe TBI = immediate ICU
HERNIATION SYNDROMES	UNCAL (temporal lobe through tentorial notch → CN III compression → ipsilateral blown pupil then contralateral hemiplegia — Kernohan's notch = false localising sign); CENTRAL (bilateral small pupils, loss of upward gaze, decorticate→decerebrate); TONSILLAR (foramen magnum → medullary compression → cardiorespiratory arrest)	IPSILATERAL BLOWN PUPIL = UNCAL HERNIATION = EMERGENCY; Decorticate = cortical lesion; Decerebrate = midbrain/pontine lesion (worse prognosis)

5. Management of Raised ICP — Tiered Approach

Tier / Method	Intervention	Mechanism	Target/Details
TIER 1 — Head Position	Head-up 30°; neutral neck position; avoid tight ETT ties	Facilitates jugular venous drainage → ↓ cerebral venous pressure → ↓ ICP by 2–5 mmHg	30° head-up = optimal; >30° may reduce MAP disproportionately
TIER 1 — Normocapnia	PaCO₂ 35–40 mmHg; avoid hyper/hypocapnia; controlled ventilation with EtCO₂ monitoring	CO₂ = most potent physiological regulator of CBF (2–3% per mmHg)	EtCO₂ 35–38 mmHg correlates with PaCO₂ 38–42 mmHg; PROPHYLACTIC hyperventilation AVOIDED
TIER 1 — Normoglycaemia	Blood glucose 6–10 mmol/L; avoid hypo/hyperglycaemia	Hyperglycaemia → lactate in ischaemic neurons → acidosis → cell death; increases BBB permeability	Hourly glucose monitoring; insulin sliding scale
TIER 1 — Normothermia	Temperature 36–37.5°C; treat fever aggressively; avoid hyperthermia	Each 1°C ↑ temperature → CMRO₂ ↑7% → ↑CBF → ↑ICP	Continuous temperature monitoring; cooling; antipyretics
TIER 1 — Analgesia and Sedation	Adequate analgesia; sedation to prevent coughing/bucking; propofol, remifentanil, fentanyl	Propofol: ↓CMRO₂ 25–50% → ↓CBF → ↓ICP; caution: PRIS >4–5 mg/kg/hr >48h	RASS -1 to -3; avoid daily sedation interruption in active intracranial hypertension
TIER 2 — Mannitol	0.25–1.0 g/kg IV over 20–30 min; repeat q4–6h; monitor osmolality (<320 mOsm/L)	Immediate plasma expansion effect + sustained osmotic effect (draws water from brain across intact BBB)	FIRST-LINE; CONTRAINDICATED: osmolality >320, severe hypovolaemia, anuria
TIER 2 — Hypertonic Saline (HTS)	3% NaCl 150–300 mL; 23.4% NaCl 30 mL bolus; target Na⁺ 145–155 mEq/L	Osmotic mechanism + restores membrane potential; does NOT cause diuresis — improves cardiac output	NOW PREFERRED in hypovolaemia/haemorrhagic shock with TBI; complications: hypernatraemia, ODS
TIER 3 — Therapeutic Hyperventilation	Short-term PaCO₂ 30–35 mmHg as rescue bridge	↓PaCO₂ → vasoconstriction → ↓CBV → ↓ICP by 5–10 mmHg within minutes	USE ONLY AS BRIDGE; duration <30 min; not below 25 mmHg
TIER 3 — CSF Drainage (EVD)	External ventricular drain via Kocher's point	Direct removal of CSF → ↓ intracranial volume → ↓ ICP	GOLD STANDARD for ICP measurement; complications: infection, haemorrhage
TIER 3 — Decompressive Craniectomy	Surgical removal of bone flap; dura patched	Removes the "rigid container" limitation; RESCUEicp: fewer deaths but ↑ vegetative state	Indication: refractory ICP >20 mmHg despite tier 1–2 + resectable haematoma
TIER 3 — Barbiturate Coma	Thiopentone 2–4 mg/kg bolus then 1–3 mg/kg/hr; titrate to burst-suppression	↓CMRO₂ to max 50%; proportional ↓CBF → ICP reduction of 10–20 mmHg	LAST RESORT — haemodynamic toxicity, immune suppression, prolonged emergence
TIER 3 — Hypothermia	Mild (33–35°C) or moderate (32–34°C) targeted temperature management	↓CMRO₂ 6–7% per °C → ↓CBF → ↓ICP	EUROTHERM3235: mild hypothermia → WORSE outcomes; rebound ICP on rewarming — must be gradual
Dexamethasone	8 mg IV loading → 4 mg q6h	↓Tumour-associated BBB disruption and vasogenic oedema; TUMOUR-SPECIFIC benefit	USE ONLY for vasogenic oedema around tumours; AVOID in TBI (CRASH trial → ↑mortality) and stroke

★ EXAMINER'S PEARL

ICP normal 5-15 mmHg; treatment threshold >20-22 mmHg. CPP = MAP − ICP; target ≥60 mmHg in TBI (BTF 2016). Monro-Kellie doctrine: fixed volume skull; brain (80%) + CSF (10%) + blood (10%) = constant. CSF: produced by CHOROID PLEXUS (0.35 mL/min = 500 mL/day, 3-4x daily turnover); flows lateral ventricles → foramen of Monro → 3rd ventricle → AQUEDUCT OF SYLVIUS (most common obstruction site) → 4th ventricle → foramina of Luschka (×2) + Magendie (×1) → subarachnoid space → ARACHNOID GRANULATIONS in superior sagittal sinus → venous blood. Features of raised ICP: morning headache, projectile vomiting (medullary), papilloedema (takes 24-48h), CUSHING'S TRIAD (PRE-TERMINAL), blown ipsilateral pupil (uncal herniation). Management tiers: TIER 1 (head-up 30°, normocapnia, normoglycaemia, normothermia, propofol sedation); TIER 2 (MANNITOL or HYPERTONIC SALINE); TIER 3 (brief hyperventilation rescue, EVD drainage, decompressive craniectomy, barbiturate coma, hypothermia). DEXAMETHASONE only for tumour vasogenic oedema (NOT TBI).

References: Brain Trauma Foundation. Guidelines for Management of Severe TBI 4th Ed 2016. Cooper DJ et al. RESCUEicp — NEJM 2011. EUROTHERM3235 trial — NEJM 2015. Czosnyka M, Pickard JD. Monitoring and interpretation of ICP. J Neurol Neurosurg Psychiatry 2004.

"

Define FRC and discuss its physiological significance during general anaesthesia. Enumerate the factors that decrease FRC perioperatively. Explain the mechanism and clinical utility of PEEP in restoring FRC.

A. Definition and Composition of FRC 1 mark

B. Physiological Significance of FRC During General Anaesthesia 2 marks

C. Factors Decreasing FRC Perioperatively 3 marks

D. Mechanism and Clinical Utility of PEEP in Restoring FRC 4 marks

Write short notes on: (a) Zones of West in the lung and their significance under mechanical ventilation [5] (b) Hypoxic Pulmonary Vasoconstriction (HPV) and factors blunting it [5]

A. Zones of West 5 marks

B. Hypoxic Pulmonary Vasoconstriction 5 marks

Detail the boundaries, contents, and ligaments traversed during epidural puncture [5]. Explain the physiological factors governing the spread of local anaesthetics within the epidural space [5].

A. Anatomy of the Epidural Space 5 marks

B. Factors Governing LA Spread in the Epidural Space 5 marks

Describe the principles of Train-of-Four (TOF) and Double Burst Stimulation (DBS) [4]. Explain the phenomenon of 'fade' and 'post-tetanic facilitation' in depolarising vs. non-depolarising blocks [6].

A. Train-of-Four (TOF) Monitoring 2 marks

B. Double Burst Stimulation (DBS) 2 marks

C. Fade and Its Mechanism 3 marks

D. Post-Tetanic Facilitation (PTF) 3 marks

E. Comparison: Depolarising vs Non-Depolarising Block Patterns

Describe the pharmacology of dexmedetomidine: (a) Mechanism of action and receptor selectivity profile [3] (b) Clinical applications in modern anaesthesia and ICU [4] (c) Adverse effects and contraindications [3].

A. Mechanism of Action & Receptor Profile 3 marks

B. Clinical Applications 4 marks

C. Adverse Effects and Contraindications 3 marks

Explain the physical principle of infrared absorption spectroscopy [3]. Draw and analyse a normal capnograph waveform, labelling its distinct phases [4]. Describe capnograph variations in bronchospasm, cardiac arrest, and rebreathing [3].

A. Physical Principle — Infrared Absorption Spectroscopy 3 marks

B. Normal Capnograph Waveform — Four Phases 4 marks

C. Pathological Capnograph Variations 3 marks

Write short notes on: (a) Sugammadex: Mechanism of action, dosing criteria, and limitations [5] (b) Hofmann elimination and ester hydrolysis with reference to Cisatracurium and Remifentanil [5].

A. Sugammadex 5 marks

B. Hofmann Elimination & Ester Hydrolysis 5 marks

Describe the anatomy of the NMJ. Discuss normal physiology. Describe depolarising and non-depolarising muscle relaxants. Discuss tests for neuromuscular block monitoring.

Discuss in detail the anatomy of the brachial plexus. Enumerate and describe various blocks used to block the brachial plexus at various levels.

Define ICP and CPP. Discuss CSF circulation in detail. Discuss the various methods used in OT and ICU to manage raised ICP. What are the features of raised ICP?

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews